Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

NCT04164069 is registered in ClinicalTrials.gov with Anne Noonan as lead sponsor.

NCT NCT04164069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04164069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Lead sponsor
Anne Noonan
Phase
Phase 1
Overall status
Completed
Start date
September 2, 2020
Completion date
June 22, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal carcinoma, bile duct cancer, esophageal cancer, gall bladder cancer, gastric cancer, metastatic colorectal carcinoma, pancreatic cancer, small bowel adenocarcinoma, stage ii colon cancer, stage ii rectal cancer, stage iii colon cancer, stage iii rectal cancer, stage iv colorectal cancer ajcc v8, stage iva colorectal cancer ajcc v8, stage ivb colorectal cancer ajcc v8, stage ivc colorectal cancer ajcc v8